Comparison of in vitro Efficacy of Quinopristin /Dalfopristin, Linezolid and Vancomycin for Methicillin Resistant Staphylococcus Aureus
Keywords:
Methicillin Resistant Staphylococcus aureus, Minimum Inhibitory concentration, Epsilometer Test, Vancomycin Intermediate Staphylococcus aureus,, Vancomycin Intermediate Staphylococcus aureus, Vancomycin Resistant Staphylococcus aureus, Clinical Laboratory and Standard Institute.Abstract
Objectives: To compare the in vitro activity of quinopristin/dalfopristin, linezolid and vancomycin by
determining their minimum inhibitory concentrations (MICs) for methicillin-resistant Staphylococcus
aureus (MRSA) isolated from various clinical samples received from LGH, Lahore.
Study Design : Comparative Study
Place and Duration of Study: Pathology Department, Post Graduate Medical Institute, Lahore from
February 2013 to October 2013.
Methodology: The MIC of quinopristin/dalfopristin, linezolid and vancomycin for 50 MRSA strains
were determined by using E-test strips (AB Biodisk, Biomeurix) and results were interpreted according
to clinical and laboratory standards institute (CLSI) guidelines.
Results: All the isolates showed 100% susceptibility to linezolid and quinopristin/dalfopristin and currently
no resistant strain was found for these drugs. Quinopristin/dalfopristin showed lowest MIC
values than Linezolid and vancomycin.
Conclusion: The study provided the in vitro information in establishing the role of linezolid and
quinopristin/dalfopristin as an alternative to vancomycin for the treatment of serious MRSA infections.
It also gives information regarding linezolid and quinopristin/dalfopristin as the best therapeutic option
for the treatment of hVISA, VISA and VRSA.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Faiqa Arshad, Iffat Javed, Tajammal Mustafa, Sohaila Mushtaq
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
